1-20 of 49
Betsy Laplant
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A First in Human Phase I Trial (LS1681) of Abraxane/Rituximab 160 Nm Nanoparticle (AR160) in Relapsed Refractory B-Cell Lymphomas Including Transformed Follicular Lymphoma: A Final Report

Free
Thomas M. Habermann, Betsy LaPlant, Ivana Micallef, Heidi Diann Finnes, Jill Schimke, Robin Klebig, Nikki Hanley, Rebecca L. King, Thomas E. Witzig, Svetomir Markovic
Journal: Blood
Blood (2023) 142 (Supplement 1): 4471.
https://doi.org/10.1182/blood-2023-175014
Published: 2023
Journal Articles

Phase II Study Assessing Safety and Preliminary Efficacy of High Dose Intravenous Ascorbic Acid in Patients with TET2 Mutant Clonal Cytopenias

Free
Zhuoer Xie, Kristen McCullough, Terra L Lasho, Jenna A. Fernandez, Christy M Finke, Michelle Renee Amundson, Betsy LaPlant, Abhishek Mangaokar, Naseema Gangat, Kaaren K. Reichard, Michelle Ann Elliott, Thomas E. Witzig, Mrinal M. Patnaik
Journal: Blood
Blood (2023) 142 (Supplement 1): 4611.
https://doi.org/10.1182/blood-2023-186595
Published: 2023
Journal Articles

Cumulative Deficits Frailty Index and Relationship Status Predict Survival in Patients with Multiple Myeloma

Free
Nadine Abdallah, Paul DiZona, Amanika Kumar, Betsy LaPlant, Terri Menser, Sarah Aug, Megan Weivoda, Joselle Cook, Francis Buadi, Suzanne R. Hayman, Angela Dispenzieri, Martha Lacy, Morie A Gertz, S. Vincent Rajkumar, Shaji Kunnathu Kumar
Journal: Blood
Blood (2023) 142 (Supplement 1): 1986.
https://doi.org/10.1182/blood-2023-187845
Published: 2023
Journal Articles

Fixed Duration Daratumumab, Ixazomib, Lenalidomide, and Dexamethasone Quadruplet for Newly Diagnosed Multiple Myeloma - MRD Negativity and Survival Outcomes

Free
Shaji K Kumar, Betsy Laplant, Erik J Asmus, Francis K. Buadi, Wilson I. Gonsalves, Eli Muchtar, David Dingli, Melanie Ann Thompson, Ronald Go, Rahma M Warsame, Taxiarchis Kourelis, Yi L. Hwa, Amie Fonder, Miriam A. Hobbs, Martha Q. Lacy, Angela Dispenzieri, Suzanne R. Hayman, Nelson Leung, Moritz Binder, S. Vincent Rajkumar, Morie A Gertz, Prashant Kapoor
Journal: Blood
Blood (2022) 140 (Supplement 1): 10142–10143.
https://doi.org/10.1182/blood-2022-169046
Published: 2022
Journal Articles

Phase II Study of Ibrutinib in Combination with Ixazomib in Patients with Waldenström Macroglobulinemia (WM)

Free
Sikander Ailawadhi, Ricardo D Parrondo, Betsy Laplant, Victoria R. Alegria, Jamie B Elliott, Ashley Zimmerman, Keisha Heslop, Dustin Chapin, Taimur Sher, Vivek Roy, Ahsan Rasheed, Aneel Paulus, Asher Chanan-Khan
Journal: Blood
Blood (2022) 140 (Supplement 1): 9331–9332.
https://doi.org/10.1182/blood-2022-165377
Published: 2022
Journal Articles

Phase II Study Assessing Safety and Preliminary Efficacy of High Dose Intravenous Ascorbic Acid in Patients with TET2 Mutant Clonal Cytopenias of Undetermined Significance

Free
Zhuoer Xie, Kristen McCullough, Terra Lasho, Jenna A. Fernandez, Christy Finke, Michelle Renee Amundson, Betsy Laplant, Abhishek A. Mangaonkar, Naseema Gangat, Kaaren K. Reichard, Michelle A Elliott, Thomas E. Witzig, Mrinal M.M. Patnaik
Journal: Blood
Blood (2022) 140 (Supplement 1): 2893–2894.
https://doi.org/10.1182/blood-2022-165163
Published: 2022
Journal Articles

Phase II Trial of Elotuzumab with Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM) in the Post-Daratumumab Progression Setting

Free
Sikander Ailawadhi, Ricardo D Parrondo, Betsy Laplant, Victoria R. Alegria, Jamie B Elliott, Taimur Sher, Aneel Paulus, Dustin Chapin, Keisha Heslop, Asher Chanan-Khan, Vivek Roy
Journal: Blood
Blood (2022) 140 (Supplement 1): 4450–4451.
https://doi.org/10.1182/blood-2022-164656
Published: 2022
Journal Articles

Fixed Duration Therapy with Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone for High Risk Smoldering Multiple Myeloma-Results of the Ascent Trial

Free
Shaji K Kumar, Melissa Alsina, Betsy Laplant, Ashraf Z. Badros, Al-Ola Abdallah, Rafat Abonour, Erik J Asmus, Binod Dhakal, Cara A. Rosenbaum, Daniel Egan, Manisha Bhutani, Andrzej Jakubowiak, Brian G.M. Durie
Journal: Blood
Blood (2022) 140 (Supplement 1): 1830–1832.
https://doi.org/10.1182/blood-2022-168930
Published: 2022
Journal Articles

Time-Limited Maintenance with Ibrutinib after First-Line Therapy and the Incremental Impact on Minimal Residual Disease (MRD) for Patients with Chronic Lymphocytic Leukemia (CLL)

Free
Sikander Ailawadhi, Ricardo D Parrondo, Aneel Paulus, Betsy Laplant, Victoria R. Alegria, Ashley Zimmerman, Dustin Chapin, Taimur Sher, Vivek Roy, Asher Chanan-Khan
Journal: Blood
Blood (2022) 140 (Supplement 1): 9904–9905.
https://doi.org/10.1182/blood-2022-164667
Published: 2022
Journal Articles

PET2 Response Associated with Survival in Newly Diagnosed Diffuse Large B-Cell Lymphoma: Results of Two Independent Prospective Cohorts

Free
Sanjal H Desai, Levi D. Pederson, Betsy Laplant, Raphael Mwangi, Matthew J. Maurer, Jason R. Young, William R. Macon, Rebecca L. King, Yucai Wang, James R. Cerhan, Andrew L. Feldman, David J. Inwards, Ivana N. Micallef, Patrick B. Johnston, Luis F. Porrata, Stephen M. Ansell, Thomas M. Habermann, Thomas E. Witzig, Grzegorz S. Nowakowski
Journal: Blood
Blood (2021) 138 (Supplement 1): 2508.
https://doi.org/10.1182/blood-2021-151276
Published: 2021
Journal Articles

Parsaclisib in Combination with R-CHOP for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: Preliminary Results of a Phase 1/1b Study

Free
Yucai Wang, Betsy Laplant, Rebecca L. King, Ivana N. Micallef, Stephen M. Ansell, Han W. Tun, Madiha Iqbal, Gita Thanarajasingam, Allison C. Rosenthal, David J. Inwards, Patrick B. Johnston, Luis F. Porrata, Thomas M. Habermann, Thomas E. Witzig, Grzegorz S. Nowakowski
Journal: Blood
Blood (2021) 138 (Supplement 1): 1415.
https://doi.org/10.1182/blood-2021-147507
Published: 2021
Journal Articles

Impact of Double Hit Lymphoma and Cell of Origin in the Risk of Central Nervous System Relapse in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma

Free
Xavier Andrade-Gonzalez, Raphael Mwangi, Jithma P. Abeykoon, Paul J. Hampel, Saurabh Zanwar, Betsy Laplant, Gita Thanarajasingam, Umar Farooq, Matthew J. Maurer, Thomas E. Witzig, Thomas M. Habermann, Jose C. Villasboas, Anne J. Novak
Journal: Blood
Blood (2021) 138 (Supplement 1): 1439.
https://doi.org/10.1182/blood-2021-151973
Published: 2021
Journal Articles

Aggressive Smoldering Curative Approach Evaluating Novel Therapies (ASCENT): A Phase 2 Trial of Induction, Consolidation and Maintenance in Subjects with High Risk Smoldering Multiple Myeloma (SMM): Initial Analysis of Safety Data

Free
Shaji K. Kumar, MD, Al-Ola Abdallah, MD, Ashraf Z. Badros, MD, Betsy Laplant, MS, Binod Dhakal, MS, Melissa Alsina, MD, Rafat Abonour, MD, Cara A. Rosenbaum, MD, William I Bensinger, MD, Manisha Bhutani, MD, Andrzej Jakubowiak, MD PhD, Erica Kim, Brian G.M. Durie, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 35–36.
https://doi.org/10.1182/blood-2020-142584
Published: 2020
Journal Articles

Daratumumab, Ixazomib, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma

Free
Shaji K. Kumar, MD, Prashant Kapoor, MD, Betsy Laplant, MS, Liang Phuong-Dung, Eli Muchtar, MD, Francis K. Buadi, MB, CHB, Wilson I Gonsalves, MD, Gabriella C Malave, BA, Alanna M. Vossen, David Dingli, MD PhD, Ronald S. Go, MD, Rahma M Warsame, MD, Taxiarchis Kourelis, MD, Yi L. Hwa, NP, Amie Fonder, PA-C, MS, Miriam A. Hobbs, APRN, CNP, DNP, John A. Lust, MD PhD, Martha Q. Lacy, MD, Angela Dispenzieri, MD, Suzanne R. Hayman, MD, Nelson Leung, MD, S. Vincent Rajkumar, MD, Morie A. Gertz, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 36–37.
https://doi.org/10.1182/blood-2020-139372
Published: 2020
Journal Articles

Phase 2 Trial of Ixazomib, Cyclophosphamide and Dexamethasone for Treatment of Previously Untreated Light Chain Amyloidosis

Free
Eli Muchtar, MD, Morie A Gertz, MD, Betsy Laplant, MS, Francis K. Buadi, MB, CHB, Nelson Leung, MD, Stephanie M. Peterson, P. Leif Bergsagel, MD, Amie Fonder, PA-C, MS, Yi L. Hwa, NP, Miriam A. Hobbs, APRN, CNP, DNP, Dania Kaehlyn Helgeson, Alanna M. Vossen, Wilson I Gonsalves, MD, Martha Q. Lacy, MD, Prashant Kapoor, MD, Mustaqeem A. Siddiqui, MDMBA, Jeremy Larsen, Rahma M Warsame, MD, Suzanne R. Hayman, MD, Ronald S. Go, MD, David Dingli, MD PhD, Taxiarchis Kourelis, MD, Angela Dispenzieri, MD, S. Vincent Rajkumar, MD, Shaji K. Kumar, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 52–53.
https://doi.org/10.1182/blood-2020-138814
Published: 2020
Journal Articles

Lenalidomide/RCHOP (R2CHOP) Produces High Response Rates and Overall Survival in New, Untreated Diffuse Large B Cell Lymphoma Transformed from Follicular Lymphoma- Results from MC078E

Free
Sanjal H Desai, MD, Betsy Laplant, MS, William R. Macon, MD, Rebecca L. King, MD, Yucai Wang, MDPhD, David J. Inwards, MD, Ivana Micallef, MD, Patrick B. Johnston, Luis F. Porrata, MD, Stephen M. Ansell, MD PhD, Thomas M. Habermann, MD, Thomas E. Witzig, MD, Grzegorz S. Nowakowski, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 47–48.
https://doi.org/10.1182/blood-2020-141298
Published: 2020
Journal Articles

Phase 2 Trial of Daratumumab, Ixazomib, Lenalidomide and Modified Dose Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma

Free
Prashant Kapoor, MD, Morie A. Gertz, MD, Betsy Laplant, MS, Gabriella C Malave, BA, Eric Wolfe, Eli Muchtar, MD, Mustaqeem A. Siddiqui, MDMBA, Wilson I Gonsalves, MD, Angie R. Emanuel, Taxiarchis Kourelis, MD, Rahma Warsame, MD, David Dingli, MD PhD, Francis K. Buadi, MB, CHB, Suzanne R. Hayman, MD, Nelson Leung, MD, Yi L. Hwa, APRN, CNP, DNP, Miriam A. Hobbs, APRN, CNP, DNP, Amie Fonder, PA-C, MS, Angela Dispenzieri, MD, Martha Q. Lacy, MD, S. Vincent Rajkumar, MD, Shaji K. Kumar, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 864.
https://doi.org/10.1182/blood-2019-131476
Published: 2019
Journal Articles

The DIAL Study (Dual Immunomodulation in Aggressive Lymphoma): A Randomized Phase 2 Study of CDX-1127 (Varlilumab) in Combination with Nivolumab in Patients with Relapsed or Refractory Aggressive B-Cell Lymphomas (NCI 10089 / NCT03038672)

Free
Jose C Villasboas, MD, Craig B. Reeder, MD, Han W. Tun, MD, Nancy L Bartlett, MD, Elad Sharon, MD MPH, Betsy Laplant, MS, Alex A Adjei, MD PhD, Justin Kline, MD, Francisco J. Hernandez-Ilizaliturri, MD, Farrukh T. Awan, MD, Sumana Devata, MD, Aleksandr Lazaryan, MDPhDMPH, Lawrence E Morris, MD, Stephen M Ansell, MD PhD, Catherine Diefenbach, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1591.
https://doi.org/10.1182/blood-2019-130449
Published: 2019
Journal Articles

Maximizing FDG-PET/CT Utility in Staging of Follicular Lymphoma (FL): The Role of Spleen Involvement and Bone Standardized Uptake Values

Free
Frederique St-Pierre, MD, Stephen Broski, MD, Betsy Laplant, MS, Thomas M. Habermann, MD, Thomas E. Witzig, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2811.
https://doi.org/10.1182/blood-2019-131992
Published: 2019
Journal Articles

A Prospective Pilot Study of Ixazomib, Lenalidomide, and Dexamethasone for Patients with Newly Diagnosed or Relapsed/Refractory POEMS Syndrome

Free
Angela Dispenzieri, MD, Michelle Mauermann, Betsy Laplant, MS, Martha Q. Lacy, MD, Ronald S. Go, MD, Prashant Kapoor, MD, Yi L. Hwa, APRN, CNP, DNP, Amie Fonder, PA-C, MS, Miriam A. Hobbs, APRN, CNP, DNP, Francis K. Buadi, MB, CHB, Suzanne R. Hayman, MD, Nelson Leung, MD, John A. Lust, MD PhD, David Dingli, MD PhD, Wilson I Gonsalves, MD, Taxiarchis Kourelis, MD, Rahma M Warsame, MD, S.Vincent Rajkumar, MD, Shaji K. Kumar, MD, Morie A Gertz, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1846.
https://doi.org/10.1182/blood-2019-127366
Published: 2019